P/E ratio for Roche (ROG.SW)
P/E ratio at the end of 2022: 18.9
According to Roche's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.354. At the end of 2022 the company had a P/E ratio of 18.9.
P/E ratio history for Roche from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 18.9 | -18.23% |
| 2021 | 23.2 | 29.87% |
| 2020 | 17.8 | -15.58% |
| 2019 | 21.1 | -0.99% |
| 2018 | 21.3 | -17.87% |
| 2017 | 26.0 | 12.51% |
| 2016 | 23.1 | -19.56% |
| 2015 | 28.7 | 7.95% |
| 2014 | 26.6 | 44.51% |
| 2013 | 18.4 | 11.26% |
| 2012 | 16.5 | 11.32% |
| 2011 | 14.9 | 7.43% |
| 2010 | 13.8 | -37.01% |
| 2009 | 22.0 | 23.37% |
| 2008 | 17.8 | -16.64% |
| 2007 | 21.4 | -32.25% |
| 2006 | 31.5 | -22.32% |
| 2005 | 40.6 | 94.98% |
| 2004 | 20.8 | -54.94% |
| 2003 | 46.2 | -336.57% |
| 2002 | -19.5 | -174.53% |
| 2001 | 26.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -27.92% | 🇺🇸 USA |
 Novartis NVS | 24.8 | 72.43% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -4.90% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.4 | 146.75% | 🇺🇸 USA |
 Amgen AMGN | 18.6 | 29.36% | 🇺🇸 USA |
 Sanofi SNY | 14.3 | -0.57% | 🇫🇷 France |
 Becton Dickinson BDX | 42.0 | 192.66% | 🇺🇸 USA |
 Merck MRK | 68.7 | 378.92% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.2 | -21.85% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.